drugset / Trial / NCT00770653

Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.

NCT00770653

Phase 3 Completed 305 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare pioglitazone and metformin combination therapy, twice daily (BID), to glimepiride and metformin combination therapy for treating diabetic subjects with dyslipidemia.

Timeline

Start
2007-04
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glimepiride Small molecule 2 mg Oral
Subject Pioglitazone Small molecule 15 mg Oral
Background Metformin Small molecule 850 mg Oral